NCT00940329View on ClinicalTrials.gov

Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

July 31, 2004

Study Completion Date

December 31, 2004

Conditions
Healthy
Interventions
DRUG

Roflumilast

Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)

DRUG

Roflumilast

Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)

Trial Locations (1)

78467

Nycomed, Konstanz

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY